ImmunityBio Inc. Common Stock vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? ImmunityBio Inc. Common Stock trades at $10.53 (market cap $10.51B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.69 (market cap $141.25M). The key difference: ImmunityBio Inc. Common Stock is far larger — about 74.4× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 1 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| IBRX | KOLD | |
|---|---|---|
Market Cap | $10.51B | $141.25M |
Volume | 10,445,785 | 5,492,367 |
Sector | Health | Leveraged / Inverse |
52-Week High | $11.55 | $49.39 |
52-Week Low | $1.98 | $13.58 |
Typical Hold Time | 1 Days | 10 Days |
Enterprise Value | $10.97B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KOLD is trading at $24.475, down 1.47% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from record-high natural gas production and mild weather forecasts that are weighing on energy sector sentiment. Recent news highlights geopolitical tensions in the Middle East and supply dynamics affecting natural gas markets, creating volatility for energy-related investments.
The outlook remains cautious given the bearish technical indicators and fundamental pressures from oversupply conditions in natural gas markets. Investment opportunities exist for contrarian investors betting on geopolitical risk premiums, but risks include continued production growth and weather-dependent demand uncertainty that could pressure energy sector performance in the near term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →